Seeing if CBD reduces the effects of THC
Official title: Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy
Run by University of California, Los Angeles · NCT06859710 · Data updated 2026-11-12
This trial tests whether different doses of CBD change the effects of THC in adults who regularly use inhaled cannabis.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years to 55 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | November 5, 2025 |
| Main results expected | September 1, 2027 |
| Study ends | September 1, 2028 |
| Registry record updated | December 17, 2025 |
| Trial ID | NCT06859710 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 21–55 who inhale cannabis 1–7 days per week, are not seeking treatment for cannabis use, have BMI 18.5–34 kg/m2, are not pregnant or breastfeeding, and agree to use contraception are ideal candidates.
✕Probably not a fit
People with severe cannabis or other substance use disorders, significant psychiatric illness, recent use of other illicit drugs, pregnant or breastfeeding individuals, or those who infrequently or never use cannabis are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 1, randomized, placebo-controlled human study at UCLA gives adults who use inhaled cannabis single doses of THC with or without one of several doses of oral CBD or placebo to see how CBD modifies THC's effects. Eligible participants are 21–55 years old, use cannabis 1–7 days per week, and meet medical and psychiatric screening criteria. Researchers will collect subjective effect ratings, pain response measures, cognitive and psychiatric assessments, and safety/laboratory monitoring during and after dosing. The protocol compares placebo, THC alone, and THC combined with 20 mg, 40 mg, or 80 mg CBD to characterize dose-related modulation of both adverse and analgesic effects.
Why it matters
Potential benefit: If successful, the approach could reduce THC-related adverse effects while preserving its pain-relieving benefits.
How similar studies have gone: Prior laboratory studies report mixed results—some show CBD can blunt certain subjective and psychotic-like effects of THC, but the evidence is inconsistent and not definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or non-pregnant and non-lactating females aged 21-55 years * Report cannabis use 1-7 days per week over the month prior to screening * Not currently seeking treatment for their cannabis use * History of inhaled cannabis use * Have a Body Mass Index from 18.5 - 34 kg/m2 * Able to perform all study procedures * Must be using a contraceptive (hormonal or barrier methods) Exclusion Criteria: * Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD * Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. * Report using other illicit drugs in the prior 4 weeks * Current pain * Pregnancy * Currently enrolled in another research protocol * Not using a contraceptive method (hormonal or barrier methods) * Insensitivity to the cold water stimulus of the Cold Pressor Test * Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history. * Not able to speak and read English
Where it's running
-
UCLA Center for Cannabis and Cannabinoids
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Ziva Cooper, PhD — University of California, Los Angeles
- Study coordinator: Ziva Cooper, PhD
- Email: zcooper@mednet.ucla.edu
- Phone: 310-206-9942
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of smoked and oral THC on pain and intoxication based on age
This study is testing how different ages affect the pain relief and intoxication from smoked and oral THC, to see if it works differently for younger and older adults.
-
CGM-guided carb awareness education for adults with Type 1 diabetes
This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.
-
Protein supplements with or without spices to protect muscle for people on GLP-1 weight loss meds
This pilot test checks whether daily whey protein, with or without mixed spices, helps preserve muscle mass and strength in adults using GLP-1 weight-loss medicines.
-
Diet Quality Matters: A Nutrition Education Program for Los Angeles Food Rx Participants
A community-based program will test whether tailored nutrition education and cooking sessions can help low-income adults in LA improve diet quality and reduce cardiometabolic risk.
-
Diet quality in older adults and how two dietary tools compare
This study tests two diet-quality questionnaires in adults 60 and older who use LA Food Rx produce programs to see which better reflects their eating and BMI.
-
Neuroplastic pain education and guided breathing during awake cataract surgery
This trial tests whether the STEIN Protocol, a non-drug approach with pain education, guided imagery, and paced breathing, helps adults having cataract surgery require less pain medicine and feel less anxious.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.